Severin Schwan, Roche CEO (Sebastien Bozon/AFP via Getty Images)

Roche cuts PhII eye dis­ease pro­gram, one day af­ter an­oth­er biotech flopped in same in­di­ca­tion

Right af­ter NGM failed to meet the pri­ma­ry end­point in a Phase II eye dis­ease tri­al, one of the Big Phar­mas de­cid­ed to re­move a mid-stage can­di­date from its pipeline.

The up­date was qui­et, an­nounced in Roche’s Q3 earn­ings pre­sen­ta­tion, where the Swiss phar­ma said it was re­mov­ing HtrA1 in­hibitor gale­gen­imab from its pipeline. Roche did not bring up the de­vel­op­ment in its earn­ings call Tues­day morn­ing. How­ev­er, a Roche spokesper­son told End­points News Tues­day morn­ing via email sim­ply that:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.